What it is:Multiple sclerosis is an autoimmune disease where the immune system attacks the myelin sheath and the axons themselves in the central nervous system (brain, spinal cord, optic nerves). The true trigger is unknown, but the working theory is a T-cell and B-cell driven attack against myelin and oligodendrocytes (the cells that make myelin), amplified by macrophages, antibodies, and reactive oxygen species.
The core problem:Every lesion is a patch of stripped or damaged wiring. Strip the insulation off a wire and the signal slows, degrades, or stops. Where the lesion forms determines the symptom, which is why MS can look like almost anything neurologic depending on the patient and the moment.
What you do about it:Three separate jobs, not one. (1) Shorten and soften acute attacks with high-dose steroids. (2) Slow the underlying disease with a disease-modifying therapy (DMT), started as early as possible. (3) Manage the symptoms that are already there (spasticity, bladder issues, fatigue) because DMTs don't touch existing damage.
Think of MS management as three separate prescriptions running in parallel: a steroid burst is damage control for a flare, a DMT is the long game against future flares and silent progression, and symptomatic drugs treat whatever damage is already permanent. Mixing these up is the single most common way students get MS questions wrong; a steroid taper does not modify long-term disease course, and a DMT does not touch today's relapse.
MS is classified by how the disease behaves over time, not by a single scan or lab value. The classification a patient carries drives which drugs are even on the table.
| Course | Pattern | Notes |
|---|---|---|
| RRMS(relapsing-remitting) | Discrete attacks (new symptoms lasting at least 24 hours) followed by full or partial recovery, with stable baseline between attacks | Most common presentation at diagnosis; most DMTs are approved here |
| SPMS(secondary-progressive) | Steady decline that follows an initial relapsing-remitting course | Most RRMS patients eventually convert to this; attacks and remissions become hard to distinguish from background progression |
| PPMS(primary-progressive) | Progressive disability from the moment of diagnosis, no distinct relapses | Smaller subset; far fewer approved DMTs (ocrelizumab is the standout) |
| CIS(clinically isolated syndrome) | A single episode suggestive of MS, not yet meeting full diagnostic criteria | Risk-stratified by MRI/LP into low-risk (watch and wait) vs high-risk (treat) |
| RIS(radiologically isolated syndrome) | MRI lesions typical of MS found incidentally, no clinical symptoms at all | Monitored clinically and radiographically rather than treated |
RRMS relapses are episodic and at least partially reversible; SPMS/PPMS progression is continuous and does not remit.A relapse must last ≥24 hoursand reflect new or worsening neurologic function to count. Also remember: mitoxantrone is FDA-approved for SPMS and worsening RRMS but is essentially never usedbecause of the risk of secondary leukemia and cardiotoxicity. If a question dangles it as an answer for a young patient with mild disease, that's the trap.
The exact cause of MS is still unknown, but the accepted model is autoimmune: the immune system misidentifies myelin (and the oligodendrocytes that produce it) as foreign and mounts a sustained attack. The actual executioners of tissue damage haven't been pinned to one single culprit; it's some combination of activated macrophages, autoantibodies, inflammatory cytokines, and reactive oxygen intermediates converging on the same targets.
Lesions are not identical from patient to patient, or even from lesion to lesion in the same patient. That heterogeneity reflects differences in how far along a lesion is (early inflammatory vs old, burned-out) and possibly differences in the underlying immune mechanism driving it. This is part of why MS is so unpredictable and why "one size fits all" therapy doesn't exist.
Nearly every DMT class works by interrupting some step of immune cell activation, migration into the CNS, or survival, either by modulatingthe immune signal (interferons, glatiramer acetate, S1P modulators, fumarates, teriflunomide) or by suppressing/depletingimmune cells directly (natalizumab, the anti-CD20s, alemtuzumab, cladribine, mitoxantrone). None of these drugs repair existing demyelination. They only reduce the rate of new attacks and new lesion formation, which is exactly why early treatment matters: axonal damage that has already happened is largely irreversible.
Presentation is wildly variable between patients and even within the same patient over time, because it depends entirely on where the lesions happen to land. Signs and symptoms are grouped into three tiers, and knowing the tier tells you what you're actually treating.
| Tier | What it is | Examples |
|---|---|---|
| Primary | Direct result of demyelination itself | Optic neuritis/visual complaints, gait problems and falls, paresthesias, pain, spasticity, weakness, ataxia, speech difficulty, cognitive and psychological changes, fatigue, bowel/bladder dysfunction, sexual dysfunction, tremor |
| Secondary | Complications that arise because ofthe primary symptoms | Recurrent UTIs, urinary calculi, decubitus ulcers, osteomyelitis, osteoporosis (from immobility), respiratory infections, poor nutrition, depression |
| Tertiary | The ripple effect of chronic illness on a person's life | Financial strain, social/relationship strain, vocational loss, emotional burden |
Secondary symptoms are not "less important" symptoms, they're downstream consequencesyou can often prevent. A patient with neurogenic bladder (primary) who isn't catheterized properly ends up with recurrent UTIs and calculi (secondary). That's a counseling and monitoring opportunity, not just a primary-symptom problem.
There is no single confirmatory test for MS. Diagnosis leans on ruling out mimics, because plenty of other neurologic diseases can look like MS, and MS itself can mimic other syndromes. Formal work-up lands a patient in one of three buckets: MS(RRMS or PPMS), possible MS, or not MS. Getting to "MS" generally requires at least two separate episodes of neurologic disturbance that reflect distinct CNS damage not explained by anything else.
A first attack alone (CIS) isn't automatically "MS." The MRI (with or without LP) is used to risk-stratify: low risk of further attacksmeans watch and wait, high risk(more lesions, more inflammatory burden) means treatment is considered right away. This is the diagnostic decision point where a lot of the DMT-timing questions live.
Goals of treatment:improve overall quality of life, help the patient maintain employment, and minimize long-term disability. None of the current therapies cure MS or reverse existing damage.
Everything pharmacologic in MS sorts into exactly three buckets:
High-dose glucocorticoids shorten an attack and may lessen its severity. Doesn't change the long-term trajectory.
Alters the course of illness, reduces relapse frequency and new lesion formation, slows progression of disability over time.
Manages spasticity, bladder symptoms, sensory symptoms, and fatigue that are already present. Required even on a good DMT.
Nonpharmacologic care runs alongside all three: occupational therapyteaches new techniques and tools for daily living tasks, and physical therapyimproves strength, gait, and balance while stretching reduces spasms. Mobility aids (canes, walkers) support independence as disability accumulates.
Whether a patient starts on a lower-efficacy agent and escalates only if they break through (escalation approach) or starts on a high-efficacy agent up front (induction approach) depends on how severe the disease looks at initial presentation. This is a clinical judgment call, not a fixed rule, and it's exactly the kind of nuance the DMT algorithm (see Algorithm & Switching) is built around.
Relapses worth treating are those that are mono- or polysymptomatic, localized to the optic nerve, spinal cord, or brainstem, cause functional limitations affecting activities of daily living, or worsen progressively over a 2-week window. Not every minor symptom flicker needs a steroid burst.
| Agent | Dose | Notes |
|---|---|---|
| Methylprednisolone IV | 500-1000 mg/day IV for 3 days, occasionally up to 10 days | The workhorse. Starting within 2 weeksof symptom onset speeds functional recovery, with improvement typically beginning by 3-5 days |
| Oral prednisone or dexamethasone | Equipotent dosing to IV methylprednisolone | Can substitute for IV therapy; dexamethasone has weaker literature support |
| ACTH | - | The only agent formally FDA-approved specifically for MS exacerbations, but rarely used given cost and limited availability |
Sleep disturbance, a metallic taste in the mouth, and occasionally mild GI upset. These are common and usually tolerable given the short course; warn the patient up front so it doesn't derail adherence to the taper.
DMTs split into first-generation(interferons and glatiramer acetate, the original self-injectables) and second-generationagents (orals and newer infusions/injectables with generally higher efficacy but more monitoring burden). Every one of these is a specialty medication, dispensed only through specialty pharmacy, typically running $100,000/year or more.
| Drug (Brand) | Route | Indication | Initial / Titration | Maintenance Dose |
|---|---|---|---|---|
| First-generation - self-injectable | ||||
| Interferon β-1a (Avonex) | IM weekly | Relapsing MS | 30 mcg (6 million IU) weekly | Same - "low-potency" interferon |
| Interferon β-1a (Rebif) | SQ 3x/week | Relapsing MS | 22 mcg 3x/week | 22 or 44 mcg 3x/week - "high-potency" interferon |
| Interferon β-1b (Betaseron, Extavia) | SQ every other day | Relapsing MS | 250 mcg (8 million IU) every other day | Same - "high-potency" interferon |
| Peg-interferon β-1a (Plegridy) | SQ every 14 days | RRMS | 6.3 mcg day 1, 94 mcg day 15, 125 mcg day 29 | 125 mcg every 14 days |
| Glatiramer acetate (Copaxone, Glatopa) | SQ | CIS, RRMS | - | 20 mg daily or40 mg 3x/week |
| First-generation - IV infusion | ||||
| Mitoxantrone (Novantrone) | IV | SPMS, worsening RRMS | - | 12 mg/m² every 3 months; lifetime max 140 mg/m² |
| Second-generation - oral | ||||
| Fingolimod (Gilenya) | Oral daily | Relapsing MS, age ≥10 | - | Adult 0.5 mg daily; peds <40 kg 0.25 mg, >40 kg 0.5 mg |
| Siponimod (Mayzent) | Oral daily | Relapsing MS | 5-day up-titration (dose depends on CYP2C9 genotype) | *1/*1, *1/*2, *2/*2: 2 mg daily. *1/*3, *2/*3: 1 mg daily |
| Ozanimod (Zeposia) | Oral daily | Relapsing MS | 0.23 mg days 1-4, 0.46 mg days 5-7 | 0.92 mg daily from day 8 |
| Ponesimod (Ponvory) | Oral daily | Relapsing MS | 14-day up-titration, 2 mg → 10 mg | 20 mg daily from day 15 |
| Dimethyl fumarate (Tecfidera) | Oral BID | Relapsing MS | 120 mg BID x 7 days | 240 mg BID |
| Diroximel fumarate (Vumerity) | Oral BID | Relapsing MS | 231 mg BID x 7 days | 462 mg BID |
| Monomethyl fumarate (Bafiertam) | Oral BID | Relapsing MS | 95 mg BID x 7 days | 190 mg BID |
| Teriflunomide (Aubagio) | Oral daily | Relapsing MS | - | 7 or 14 mg daily |
| Cladribine (Mavenclad) | Oral, pulsed | RRMS, active SPMS | 2-year course, 1.75 mg/kg/year in 2 short cycles/year | No dosing for 2 years after the 2-year course completes |
| Second-generation - IV infusion | ||||
| Natalizumab (Tysabri) | IV | Relapsing MS | - | 300 mg every 4 weeks (REMS required) |
| Alemtuzumab (Lemtrada) | IV | RRMS | Course 1: 12 mg/day x 5 days | Course 2 (12 mo later): 12 mg/day x 3 days (REMS required) |
| Ocrelizumab (Ocrevus) | IV | Relapsing MS and PPMS | 300 mg, then 300 mg 2 weeks later | 600 mg every 6 months (REMS required) |
| Second-generation - self-injectable | ||||
| Ofatumumab (Kesimpta) | SQ | Relapsing MS | 20 mg weekly x 3 doses (wks 0, 1, 2) | 20 mg monthly starting week 4 |
Ocrelizumab is the only DMT with an approved PPMS indication.Mitoxantroneis the only one indicated for worsening progressive disease but is avoided due to secondary leukemia risk and a hard lifetime dose cap. Cladribine has a built-in "off" period: after the 2-year, 4-cycle course, no oral cladribine is given for the next 2 years, a dosing pattern unlike anything else on this table.
These are the original DMTs and are immunomodulatory, meaning they shift immune signaling without direct cytotoxic or bone-marrow-suppressive effects. Interferons come in "low-potency" (Avonex) and "high-potency" (Rebif, Betaseron/Extavia) tiers based on dosing frequency and magnitude. Glatiramer acetate is the one non-interferon first-generation agent; Glatopa is simply the generic version of Copaxone.
Both interferon-β1a and interferon-β1b carry a caution around depression and should be avoided in patients with untreated severe depression. This is a real prescribing gate, not just a side-effect footnote.
Injection-site reactionsare common across all the self-injectables, and glatiramer acetate specifically carries a risk of tissue necrosis at the injection site plus a post-injection reaction (chest tightness, flushing, palpitations) that can occur unpredictably at any dose.
This whole family works by trapping lymphocytes inside lymph nodes so fewer of them ever reach the CNS to cause damage. That mechanism is exactly why the adverse effect list across the group repeats itself: lymphocytopenia, infections, and cardiac conduction effects (bradyarrhythmia, AV block) because of shared receptor activity, plus macular edema and decreased pulmonary function.
Fingolimod requires first-dose observationfor bradycardia/AV block. It's contraindicated with Class I/III antiarrhythmics and in patients with recent cardiac disease or second/third-degree AV block. Ketoconazole raises fingolimod levels via 3A4 inhibition.Ponesimod requires similar cardiac screening, with a 4-hour observation window in patients with certain preexisting cardiac conditions (recent MI, unstable angina, stroke/TIA, decompensated HF, second/third-degree AV block, sick sinus syndrome).
Siponimod is unique for requiring CYP2C9 genotype testing before the first dose, since both the titration schedule and the maintenance dose depend on genotype, and it's contraindicated in the *3/*3 genotype altogether. It also interacts with 2C9 and 3A4 inhibitors/inducers.
All four require baseline and ongoing varicella zoster antibody testing, ECG, blood pressure, ophthalmic exam (for macular edema), CBC, and LFTs.Vaccine efficacy can be blunted while on fingolimod; live vaccines should be avoided during and for a period after ozanimod.
All three fumarates share flushing and GI upset as their signature nuisance effects, plus lymphocytopenia, elevated LFTs, albuminuria, and a rare but serious risk of PML.
Taking the dose with food measurably decreases flushingwith dimethyl fumarate. This is a concrete, actionable counseling point that keeps patients adherent through the early weeks.
Diroximel fumarate and monomethyl fumarateare newer entries designed around the same active pathway but with less GI adverse effect burden than dimethyl fumarate, which is their main selling point when a patient can't tolerate the original. Monitoring across the class is CBC, LFTs, and MRI.
Teriflunomideis the active metabolite of leflunomide (used in rheumatoid arthritis), which explains its overlapping toxicity profile: hepatotoxicity, Stevens-Johnson syndrome, neutropenia, TB reactivation risk, and peripheral neuropathy. It's pregnancy category Xand contraindicated in severe hepatic impairment. If rapid elimination is ever needed (pregnancy, serious adverse reaction), cholestyramine or activated charcoal accelerates clearance, since teriflunomide otherwise lingers in circulation for a long time.
Contraindicated with current malignancy, HIV or other active chronic infection, and in pregnancy or lactation. Contraindicated in females and males of reproductive potentialmore broadly, given mutagenic risk. Lymphocyte counts must be within normal limits before the first course and above 800 cells/mm³before the second. Requires HIV, HBV, HCV, and TB screening plus VZV antibody and pregnancy testing before starting.
Natalizumab blocks α4-integrin (VLA-4), preventing activated lymphocytes from adhering to and crossing the blood-brain barrier. Highly effective, but its defining risk is progressive multifocal leukoencephalopathy (PML), a potentially fatal JC virus reactivation in the brain.
Natalizumab is reserved for patients who are JCV-antibody negative, or JCV-positive only when the benefit clearly outweighs the "severe but low" PML risk, per guideline language, with an antibody index above 0.9 requiring the most caution. This is why JCV testing sits directly in the treatment algorithm(see next section) rather than being an afterthought. A REMS program is mandatory. Discontinuing natalizumab in a patient who develops PML also carries a risk of immune reconstitution inflammatory syndrome (IRIS)as immune surveillance of the CNS returns.
Monitoring: JCV antibody status, ongoing infection screening, MRI, LFTs, and watching for hypersensitivity reactions during infusion.
These deplete CD20-positive B cells, reflecting the growing recognition that B cells (not just T cells) drive MS pathology. Ocrelizumabis infused every 6 months after the loading doses and is the only DMT with a formal PPMS indication. Ofatumumabis notable for being self-injectabledespite being a B-cell depleting biologic, dosed monthly after a 3-dose loading series.
Ocrelizumab infusions require premedicationwith an antihistamine 30-60 minutes prior plus IV methylprednisolone (or equivalent) 30 minutes prior, with observation for at least 1 hour post-infusion given the risk of infusion reactions. Both agents require hepatitis B screening before the first doseand avoidance of live vaccines during and after treatment until B-cell counts recover (give live vaccines at least 6 weeks before starting for ocrelizumab, or 4 weeks before for ofatumumab; inactivated vaccines at least 2 weeks before for ofatumumab).
Ofatumumab additionally requires monitoring of serum immunoglobulins, since chronic B-cell depletion can reduce them over time and raise infection risk.
Alemtuzumab depletes CD52-positive lymphocytes broadly and is reserved for highly active disease, typically after other therapies have failed, given the depth of immune suppression it causes.
Because it wipes out such a broad swath of the immune system, alemtuzumab carries risk of secondary autoimmune disorders(thyroid disease, immune thrombocytopenic purpura, Goodpasture syndrome) that can appear months to years after infusion, plus significant infection risk. Premedicate with 1,000 mg methylprednisolone(or equivalent) immediately before infusion for the first 3 days of each course, and give herpes viral prophylaxisstarting day 1 of treatment, continued for at least 2 months after completion or until CD4+ count is at least 200 cells/mm³, whichever is later. REMS program required. Contraindicated with HIV infection.
Reproductive counseling:contraception should be used during treatment and for 4 months after each treatment course; nursing is not recommended during that same window.
An anthracenedione that suppresses bone marrow broadly. Approved for SPMS and worsening RRMS, but its use has essentially disappeared because of a lifetime cumulative dose cap of 140 mg/m²(cardiotoxicity) and a real risk of treatment-related acute myeloid leukemia (AML). Monitor CBC, ECG, LVEF, and LFTs. If it shows up as a treatment answer for a young, mildly affected patient, it's almost always the wrong choice on an exam.
The management algorithm starts the moment a patient presents with symptoms suggestive of MS and branches based on MRI findings, disease activity, and JCV status.
Antioxidant supplements (vitamins A, C, E, alpha-lipoic acid, coenzyme Q10, grape seed and pine bark extract, mangosteen, acai) have suggestive but unproven benefit, and carry a theoretical risk of stimulating the immune system further, which is exactly the opposite of what you want in an autoimmune disease. Frame this honestly with patients who ask about supplements.
DMTs don't touch symptoms that are already present. These are treated on their own track, often by symptom rather than by "MS" as a diagnosis.
| Symptom | Agents used |
|---|---|
| Spasticity | Baclofen, dantrolene, diazepam, clonazepam, tizanidine, tiagabine, gabapentin, pregabalin, botulinum toxin type A, dalfampridine |
| Bladder symptoms | Propantheline, oxybutynin, dicyclomine, DDAVP (desmopressin), imipramine, amitriptyline, prazosin, terazosin, botulinum toxin type A, solifenacin, darifenacin, trospium, hyoscyamine, mirabegron, tamsulosin, tolterodine, or self-catheterization |
| Sensory symptoms | Carbamazepine, phenytoin, amitriptyline (and other TCAs), gabapentin, lamotrigine, pregabalin, duloxetine |
| Fatigue | Amantadine, antidepressants, modafinil, methylphenidate, dextroamphetamine, armodafinil, fluoxetine |
Notice how much overlap there is with other therapeutic areas: the bladder list borrows heavily from overactive bladder management, the sensory-symptom list is basically the neuropathic pain toolbox, and the fatigue list leans on stimulants and wake-promoting agents. You already know most of these drugs; the skill here is recognizing when a "different" chief complaint is actually MS-driven.
| Parameter | When | Watching for |
|---|---|---|
| CBC | Baseline and periodically on nearly every DMT | Lymphocytopenia, neutropenia, bone marrow suppression (varies by agent) |
| LFTs | Baseline, then per-agent schedule (e.g., interferons: baseline, 1 month, every 3 months for a year, then every 6 months) | Hepatotoxicity, especially with interferons, fumarates, teriflunomide, cladribine |
| ECG / cardiac monitoring | Baseline and with first dose for S1P modulators; ongoing for mitoxantrone | Bradyarrhythmia, AV block, LVEF decline |
| Ophthalmic exam | Baseline and periodically on S1P modulators | Macular edema |
| JCV antibody status | Before starting and periodically during natalizumab | PML risk stratification |
| Varicella zoster antibody | Before starting S1P modulators and alemtuzumab | Need for pre-treatment vaccination |
| MRI | Periodically across most DMTs, and whenever relapse/progression is suspected | New or enlarging lesions, PML changes, treatment response |
| Thyroid function | Interferons; ongoing for alemtuzumab | Thyroid dysfunction, autoimmune thyroid disease |
| Depression screening | Ongoing on interferon therapy | New or worsening depression |
| Disability / relapse tracking | Every visit, over months to years | Exacerbations, hospitalizations, disease progression, disability scales such as the Expanded Disability Status Scale (EDSS) |